



## HEALTH ADVISORY

October 12, 2012

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have been working closely with public health departments on a multistate investigation of fungal meningitis among patients who received an epidural injection with a potentially contaminated steroid medication prepared by New England Compounding Center (NECC). Some of these patients suffered strokes that may have resulted from their infection. Patients who received joint injections with the product are being monitored for development of septic arthritis. The investigation is ongoing.

On September 25, 2012, the NECC, located in Framingham, MA voluntarily recalled the following lots of methylprednisolone acetate (PF) 80mg/ml:

- Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #05212012@68, BUD 11/17/2012
- Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #06292012@26, BUD 12/26/2012
- Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #08102012@51, BUD 2/6/2013

The Southern Nevada Health District (SNHD) was notified through the Nevada State Health Division by the CDC, that five vials of this medication were distributed in Clark County, Nevada. SNHD staff determined none of the product was used and the vials have subsequently been sequestered. To date, there are no known local residents associated with this outbreak.

Considering that southern Nevada has a high volume of out-of-state visitors, and Clark County residents may seek out-of-state treatment and then return home, the SNHD requests that health care providers remain vigilant to the possibility that outbreak-associated cases may present for diagnosis and treatment in Clark County. If you have any suspicion that a patient may have been exposed to the recalled methylprednisolone, please promptly report to SNHD by calling (702) 759-1389. There is detailed clinician guidance at <http://www.cdc.gov/hai/outbreaks/clinicians/index.html>. The guidance and outbreak information are updated frequently. Please share this notice with your colleagues.